Clinical Research Directory
Browse clinical research sites, groups, and studies.
SGLT2 Inhibitors and Renal Anemia in Japan: RWD
Sponsor: Boehringer Ingelheim
Summary
The objectives of the study are: 1. To compare the risk and timing of anemia onset between Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor users and non-users in patients with chronic kidney disease (CKD) from the index date to first event occurrence or the end date of each individual's follow-up. 2. To compare the following outcomes from the index date to 731 days (24 months) or the end date of each individual's follow-up: A) Longitudinal changes in laboratory values between SGLT2 inhibitor users and non-users in patients with CKD. B) Prescription patterns and treatment regimens for anemia between SGLT2 inhibitor users and non-users in patients with CKD, including analysis of medication types, dosing strategies, and duration of treatments. C) Anemia-related healthcare costs between SGLT2 inhibitor users and non-users.
Official title: Effect of SGLT2 Inhibitors on Renal Anemia and Its Management in Patients With CKD in Japan
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
15000
Start Date
2025-07-23
Completion Date
2026-09-30
Last Updated
2026-03-04
Healthy Volunteers
No
Conditions
Interventions
SGLT2 inhibitor
SGLT2 inhibitor
Locations (1)
Nippon Boehringer Ingelheim Co ., Ltd.
Tokyo, Japan